Andreas Argyrides Analyst Performance

Managing Director, Senior Biotech Analyst at Oppenheimer

Andreas Argyrides is a stock analyst at Oppenheimer in the medical sector, covering 20 publicly traded companies. Over the past year, Andreas Argyrides has issued 21 stock ratings, including buy and sell recommendations. While full access to Andreas Argyrides' proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Andreas Argyrides' coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions.

Analyst Rankings, Coverage, and Performance Statistics

Analyst Ranking

Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating MarketBeat

Average Return

00.00% 12-Month ROI

Success Rate

00.00% Profitable Ratings

Total Ratings

27 Last 3 Years

Buy Recommendations

81.48% 22 Buy Ratings

Companies Covered

20 Unique Companies

Ratings Distribution

Rating	Percentage	Count
Strong Buy	0.0%	0 ratings
Buy	81.5%	22 ratings
Hold	14.8%	4 ratings
Sell	3.7%	1 ratings

Out of 27 total stock ratings issued by Andreas Argyrides at Oppenheimer, the majority (81.5%) have been Buy recommendations, followed by 14.8% Hold and 3.7% Sell.

Best & Worst Calls

This analyst does not have any ratings with enough history to determine best and worst calls.

Exchange Coverage

Exchange	Percentage	Count
NASDAQ	100.0% of companies on NASDAQ	20 companies

Andreas Argyrides, an analyst at Oppenheimer, currently covers 20 companies listed on , with the majority traded on NASDAQ.

Coverage Focus

Sector Icon	Sector	Percentage
	Medical 20 companies	100.0%

Andreas Argyrides of Oppenheimer specializes in stock coverage within the Medical sector.

Coverage Industries

Industry	Percentage
MED - BIOMED/GENE 13 companies	65.0%
MED - DRUGS 6 companies	30.0%
PHARMACEUTICAL PREPARATIONS 1 company	5.0%

About Andreas Argyrides

Andreas Argyrides is an Executive Director and Senior Analyst covering Biotechnology. Prior to joining Oppenheimer, Andreas was Vice President and Senior Analyst covering Biotechnology at Wedbush. Prior to Wedbush, Andreas spent a decade in various roles across the healthcare industry including as healthcare sector specialist and research analyst at a long/short biotech focused hedge fund. Andreas received his BA in History and Economics with honors from New York University.

Follow on LinkedIn

Andreas Argyrides' Ratings History at Oppenheimer

Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 4 Years 5 Years All Time Timeframe

Start Date

End Date

All Ratings Strong Buy Buy Hold Sell Rating

Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.
Available with a MarketBeat All Access Subscription

12-Month ROIUpgrade to All Access to use the All ROI Filter

Export to Excel

Company	Report Date	Action	Report Date Price	12-Month Price Target	Rating	12-Month Price & ROI	Details
BNTC Benitec Biopharma	9/16/2025	Reiterated Rating	$13.60	$29.00	Outperform	$0.00 00.00% ROI
KALA KALA BIO	9/11/2025	Boost Price Target	$15.92	$33.00	Outperform	$0.00 00.00% ROI
SVRA Savara	9/8/2025	Boost Price Target	$3.72	$8.00	Outperform	$0.00 00.00% ROI
UTHR United Therapeutics	9/5/2025	Boost Price Target	$387.63	$575.00	Outperform	$0.00 00.00% ROI
MNKD MannKind	9/5/2025	Boost Price Target	$5.54	$15.00	Outperform	$0.00 00.00% ROI
MNPR Monopar Therapeutics	9/3/2025	Initiated Coverage	$33.93	$77.00	Outperform	$0.00 00.00% ROI
ABEO Abeona Therapeutics	8/15/2025	Boost Price Target	$7.25	$20.00	Outperform	$0.00 00.00% ROI
DYN Dyne Therapeutics	8/6/2025	Lower Price Target	$10.47	$13.00	Outperform	$0.00 00.00% ROI
HRMY Harmony Biosciences	6/2/2025	Initiated Coverage	$34.69	$61.00	Outperform	$0.00 00.00% ROI
DYN Dyne Therapeutics	6/2/2025	Initiated Coverage	$12.04	$34.00	Outperform	$0.00 00.00% ROI
AQST Aquestive Therapeutics	6/2/2025	Initiated Coverage	$2.71	$7.00	Outperform	$0.00 00.00% ROI
ABEO Abeona Therapeutics	6/2/2025	Initiated Coverage	$6.29	$19.00	Outperform	$0.00 00.00% ROI
KALA KALA BIO	6/2/2025	Reiterated Rating	$3.68	$15.00	Outperform	$0.00 00.00% ROI
IFRX InflaRx	5/29/2025	Lower Price Target	$0.83	$3.00	Outperform	$0.00 00.00% ROI
LQDA Liquidia Technologies	5/19/2025	Set Price Target	$18.88	$13.00	Underperform	$0.00 00.00% ROI
RANI Rani Therapeutics	5/16/2025	Lower Price Target	$0.73	$4.00	Outperform	$0.00 00.00% ROI
KRRO Korro Bio	5/13/2025	Lower Price Target	$16.11	$90.00	Outperform	$0.00 00.00% ROI
PRQR ProQR Therapeutics	5/13/2025	Lower Price Target	$1.59	$9.00	Outperform	$0.00 00.00% ROI
CNTA Centessa Pharmaceuticals	5/8/2025	Initiated Coverage	$12.41	$6.00	Outperform	$0.00 00.00% ROI
IFRX InflaRx	5/8/2025	Initiated Coverage	$1.47	$6.00	Outperform	$0.00 00.00% ROI
KROS Keros Therapeutics	1/16/2025	Lower Price Target	$10.19	$23.00	Outperform	$0.00 00.00% ROI

Stock Forecasts and Research Tools

Sign in to your free account to enjoy these benefits

• In-depth profiles and analysis for 20,000 public companies.
• Real-time analyst ratings, insider transactions, earnings data, and more.
• Our daily ratings and market update email newsletter.

Sign in to your free account to enjoy all that MarketBeat has to offer.

• Sign In
• Create Account

Your Email Address:

Email Address Required

Your Password:

Password Required

Log In

---

or

Sign in with Facebook Sign in with Google

Forgot your password?

Your Email Address:

Please enter your email address.

Please enter a valid email address

Choose a Password:

Please enter your password.

Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character.

Create My Account (Free)

---

or

Sign in with Facebook Sign in with Google

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.